Hib-meningococcal vaccine groups C and Y conjugate - GSK
Alternative Names: 792014; GSK-792014; Hib-MenCY-TT vaccine - GSK; HibMenCY-TT; MenHibrixLatest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator GlaxoSmithKline
- Developer GlaxoSmithKline; GSK
- Class Haemophilus vaccines; Meningococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Haemophilus infections; Meningococcal group C infections; Meningococcal group Y infections
Most Recent Events
- 31 Mar 2016 GlaxoSmithKline completes a phase III trial for Haemophilus infections and Meningococcal group C & Y infections in USA (NCT01978093)
- 14 Nov 2013 GlaxoSmithKline plans a phase III trial for Haemophilus infections and Meningococcal group C & Y infections in USA (NCT01978093)
- 01 Jul 2012 Launched for Haemophilus infections in USA (IM, Injection)